Previcox chiens is generally applied across therapeutic domains where additional symptomatic support is needed to address pain and inflammation in dogs. It helps address symptom clusters that interfere with daily comfort and is relevant for easing symptoms related to inflammatory or irritative states. The core therapeutic uses include the control of pain and inflammation associated with osteoarthritis and the control of postoperative pain and inflammation associated with both soft-tissue and orthopedic surgery.

Therapeutic Focus and Benefit

This medication is commonly used across conditions presenting with chronic discomfort, such as persistent lameness, stiffness, and reduced mobility linked to osteoarthritis. It provides support that helps ease the overall symptom burden, contributing to improved comfort and may assist with maintaining functional stability during the course of the condition. It is also often used during phases when symptoms become more noticeable following surgical trauma. This symptomatic relief may assist with improving day-to-day comfort and supporting physical function.

Quick Fact: Relief for Musculoskeletal Symptoms
Primary Chronic Use	Long-term management of pain from osteoarthritis (OA).
Primary Acute Use	Control of acute pain and inflammation after surgery.
Symptom Easing	Assists in easing pain, stiffness, and lameness.
Patient Benefit	Supports comfort and helps maintain physical function.

Regulatory References

1. Firocoxib Chewable Tablets For oral use in dogs only. - DailyMed

Eligibility Map: Who can and cannot use Previcox chiens

The eligibility profile for Previcox (firocoxib) is strictly defined by regulatory documents, establishing clear limitations on its use in dogs based on age, weight, health status, and concurrent treatments.

Eligibility Scope	Regulatory Status	Constraint Details
Populations Allowed	Approved for use in dogs for pain and inflammation control.	Must not be used in non-canine species.
Absolute Contraindications	Contraindicated	Pregnant or lactating bitches; dogs with known hypersensitivity to firocoxib; animals with gastrointestinal bleeding, blood dyscrasia, or haemorrhagic disorders.
Age and Weight Limits	Contraindicated (EU Labeling)	Animals less than 10 weeks of age or less than 3 kg body weight. US labeling restricts use in dogs weighing less than 12.5 lb (5.7 kg).
Conditional Use	Use with Caution	Dogs with suspected or confirmed impairment of renal, cardiac, or hepatic function require careful veterinary monitoring.
Physiological State Restriction	Avoid Use	Animals that are dehydrated, hypovolaemic, or hypotensive due to the potential risk of increased renal toxicity.
Concurrent Treatment	Must Not Be Used	Concomitant use with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or corticosteroids is prohibited.

Regulatory documents establish that Previcox is intended for use in the eligible canine population that meets minimum criteria and has no absolute contraindications. Eligibility is further constrained by conditional requirements for monitoring dogs with existing organ dysfunction.

Interactions with other medicines and products

Official regulatory information outlines specific restrictions and required monitoring for the co-administration of firocoxib with certain other substances. The profile is defined by prohibited combinations and cautions related to shared risks of toxicity.

---

Contraindicated Combinations

Substance Category	Interaction Severity	Note on Risk
Other Non-Steroidal Anti-inflammatory Drugs (NSAIDs)	Prohibited	Risk of additive gastrointestinal toxicity.
Glucocorticosteroids (Corticosteroids)	Prohibited	Risk of exacerbating gastrointestinal ulceration.

---

Pharmacodynamic and Exposure Cautions

• Renal Blood Flow Agents: Concomitant treatment with drugs that affect renal blood flow, such as Diuretics and ACE Inhibitors, requires clinical monitoring.
• Nephrotoxic Agents: Concurrent use of potentially nephrotoxic drugs should be avoided or closely observed, with specific risk noted for patients with pre-existing renal, cardiovascular, or hepatic dysfunction.
• Protein Binding: Co-administration with other highly protein-bound substances may lead to toxic effects due to competition for plasma protein binding sites.

---

Timing and Food Interaction

• Washout Period: A treatment-free period of at least 24 hours is required when switching from another anti-inflammatory substance to firocoxib.
• Food Effect: Co-administration with food delays the rate of drug absorption (increases the time to reach peak plasma concentration) but does not affect the total overall drug exposure.

Targeting the Cyclooxygenase-2 ( COX-2) Enzyme

Firocoxib acts as a selective inhibitor that exhibits high selectivity for the Cyclooxygenase-2 ( COX-2) enzyme , the inducible isoform primarily responsible for synthesizing inflammatory mediators at sites of tissue injury. This selective mechanism limits the production of key pro-inflammatory prostaglandins while intentionally sparing the constitutive Cyclooxygenase-1 ( COX-1) enzyme, which is responsible for constitutive homeostatic functions, including the generation of prostaglandins that modulate gastrointestinal mucosal defense.

---

Interrupting the Prostaglandin Synthesis Cascade

By blocking COX-2 activity, the drug effectively interrupts the biochemical cascade that generates Prostaglandin E2 ( PGE2), a signaling molecule involved in enhancing peripheral nociception and increasing vascular permeability. The resulting physiological effect is a reduction in prostaglandin-mediated signaling to peripheral nociceptors and a localized limitation of increased vascular permeability, which results in altered physiological responses within the inflammatory pathways.

How to Use Previcox chiens (Firocoxib): Standard Administration Guidelines

The administration of Previcox chiens is strictly defined by the product's standardized instructions, ensuring consistent use across its approved veterinary applications. The medication is formulated as palatable, scored chewable tablets for straightforward oral administration in dogs.

---

Approved Dosing and Schedule

The dosage regimen is fixed regardless of the specific approved indication. Adherence to a precise, weight-based calculation is required for proper use:

Dosing Parameter	Instruction
Route of Administration	Oral use only
Standard Dose	5.0 mg/kg body weight (equivalent to 2.27 mg/lb)
Frequency	Once daily
Timing in Relation to Meals	Can be administered with or without food

---

Duration and Specific Contexts

Treatment duration is guided by the condition, emphasizing the use of the lowest effective dose for the shortest necessary time:

• Postoperative Use: For the control of acute pain and inflammation, the drug is administered once daily for up to three days. The first dose must be given approximately two hours prior to surgery.
• Chronic Osteoarthritis Use: For long-term management of chronic discomfort, the drug is administered once daily, with the overall duration determined by the veterinarian's assessment.

Administration Requirements

The tablets are scored to facilitate accurate dosing, allowing for administration in half-tablet increments. The medication cannot be accurately dosed in dogs weighing less than 5.7 kg (12.5 pounds), and it is not authorized for use in animals less than 10 weeks of age.

Research Evidence / Overview of Studies for Previcox chiens

Evidence for Use in Managing Pain and Inflammation Associated with Osteoarthritis

Research exploring how symptoms related to osteoarthritis (OA) manifest and are measured in dogs includes short-term, randomized, controlled field studies. These studies primarily compared firocoxib to an inactive substance (placebo) or to other commercially available pain and inflammation control options. Studies focused on outcomes related to physical discomfort and daily functioning in dogs with naturally occurring OA.

Findings monitored patterns in veterinarian-assessed lameness scores and owner-reported scores for comfort and mobility over defined intervals (typically 30–40 days). Research provides insight into short-term changes, but the evidence is limited as follow-up durations were typically short, and long-term effects are not fully established beyond approximately 90 days. Results reflect group patterns under specific study conditions, and data for certain severe subgroups remain insufficient.

---

Evidence for Use in Controlling Postoperative Pain and Inflammation

The evidence base for managing episodes of heightened symptom activity following surgery involves short-term, blinded, controlled trials where firocoxib was evaluated in study populations undergoing soft-tissue or orthopedic procedures. Studies primarily examined the objective outcome of the requirement for rescue analgesia medication.

Trials monitored patterns related to this outcome compared to placebo over very short observation periods (typically 3–5 days). Research provides context for understanding episodic or acute changes immediately post-surgery. This evidence is limited to the immediate recovery period and does not characterize how symptoms evolve in the longer-term healing phases.

---

Long-Term Evidence and Observation Periods

Research includes tolerance studies that monitored outcomes related to physiological strain or stress and functional imbalance over longer durations, sometimes up to one year. These studies primarily monitored health parameters (e.g., clinical pathology measurements) to describe the patterns observed during extended use. However, controlled evidence comparing firocoxib to an inactive control over periods of six months or more remains limited.

What is Still Uncertain About the Research Base for Firocoxib

The reliance on subjective outcome measures (owner- and veterinarian-reported scores) and the restricted follow-up in controlled trials are recognized limitations. While evidence exists for older, geriatric dogs in the OA trials, comparative evidence for highly specific subgroups is lacking, and findings for these defined categories are uncertain. Research is ongoing to better characterize long-term symptom management, and the data do not determine whether an individual will respond similarly.

Key Studies & References

1. Firocoxib Chewable Tablets For oral use in dogs only - DailyMed
2. Previcox 227 mg - Chewable tablet | European Union Veterinary Medicines Product Database (EPAR)

Common questions about Previcox chiens (FAQ)

Q: Can Previcox be used in dogs for conditions other than osteoarthritis and post-operative pain?

According to the official product information, Previcox is specifically indicated for the alleviation of pain and inflammation associated with osteoarthritis, and for the reduction of pain and inflammation associated with soft-tissue, orthopedic, and dental surgery in dogs. Its use for other conditions is not listed in the regulatory documents.

Q: Is Previcox a steroid or a non-steroidal anti-inflammatory drug (NSAID)?

Regulatory documents state that Previcox contains firocoxib, which is classified as a non-steroidal anti-inflammatory drug (NSAID). NSAIDs work by targeting enzymes that cause pain and inflammation, and are chemically distinct from steroids.

Q: How quickly can I expect Previcox to start working for my dog's pain?

Official information indicates that firocoxib, the active ingredient in Previcox, is rapidly absorbed after oral administration. It is designed to start acting quickly to help alleviate pain and inflammation in dogs. Specific onset-of-action details, including information related to the condition being treated, are detailed in the product documentation.

Q: Does Previcox require a prescription from a veterinarian?

Previcox is a veterinary medicine that is subject to medical prescription. This means that a veterinarian must prescribe it, and it can only be obtained with their authorization and guidance.

Q: What should I do if my dog misses a dose of Previcox?

Regulatory documents emphasize following the veterinarian's instructions closely for administration. If a dose is missed, regulatory information directs users to follow the prescribing veterinarian’s instructions, as they determine the appropriate next steps for the treatment schedule.

Q: Can Previcox be crushed or mixed with food to help my dog take it?

The official product information notes that Previcox tablets are palatable for dogs and can be given with or without food. They are scored, allowing them to be broken to facilitate accurate dosing, but consultation with a veterinarian is recommended before crushing tablets entirely or altering the intended method of administration.

Q: Can Previcox be used long-term for chronic conditions like osteoarthritis?

Studies and official information indicate that Previcox is suitable for the long-term management of pain and inflammation associated with chronic osteoarthritis in dogs. Consistent with official recommendations, long-term use requires continuous monitoring and guidance from a veterinarian.

How to Store and Dispose of Previcox Chewable Tablets

Storage and disposal of Previcox (firocoxib) must strictly follow the conditions specified in the official regulatory labeling.

---

Storage Conditions

Previcox chewable tablets must be stored at a temperature below 30 C or within the U.S. specified Controlled Room Temperature range of 15 C to 30 C.

• Packaging: The medication must be kept in its original package.
• Split Tablets: A half tablet, if necessary for dosing, must be returned to the blister and may be stored for a maximum of seven days.

Safety and Disposal

To prevent accidental ingestion, the medication must be stored securely and kept out of the sight and reach of children and out of reach of all pets.

Unused or expired product and any related waste materials must be disposed of in accordance with local requirements to ensure compliance with environmental standards.